June, 2025
June 2025
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  
Harold J. Burstein: First-Line Camizestrant for Emerging ESR1-Mutated Advanced Breast Cancer
Jun 3, 2025, 09:15

Harold J. Burstein: First-Line Camizestrant for Emerging ESR1-Mutated Advanced Breast Cancer

Harold J. Burstein, Breast Cancer Specialist and Professor at Harvard Medical School, posted on X:

“The NEJM has published SERENA-6 data ahead of ASCO25 plenary.
Cami joins other SERDS (elacestrant, imlunestrant, vepdegestrant) with activity in ESR1mut BC
Key questions to think about ahead of session:
1. Intensive ctDNA screening of 10 patients to find 1 who might qualify for ‘switching’ based on ESR1mut. Worthwhile?
2. Does switching among asymptomatic patients with no radiological progression make sense when drug could be added later at progression?
3. Is this fundamentally different than switching treatment based on small upticks in serum tumor markers, without overt progression?
4. Adds to data from EMBER-3 that SERD + CDK46i looks to be effective. Is 2nd line CDK46i now the standard?”

Title: First-Line Camizestrant for Emerging ESR1-Mutated Advanced Breast Cancer

Authors: François-Clément Bidard, Erica L. Mayer, Yeon Hee Park, Wolfgang Janni, Cynthia Ma, Massimo Cristofanilli, Giampaolo Bianchini, Kevin Kalinsky, Hiroji Iwata, Stephen Chia, Peter A. Fasching, Adam Brufsky, Zbigniew Nowecki, Javier Pascual, Lionel Moreau, Shin-Cheh Chen, Nuri Karadurmus, Einav Nili Gal-Yam, Kyung Hae Jung, Sonia Pernas, Sasha McClain, Wei He, Teresa Klinowska, Cynthia Huang-Bartlett, Nicholas C. Turner

Read The Full Article at NEJM.

Harold J. Burstein: First-Line Camizestrant for Emerging ESR1-Mutated Advanced Breast Cancer

More posts featuring ASCO25.